EXEL Exelixis Inc.

21.52
+0.3  (+1%)
Previous Close 21.22
Open 21.22
Price To Book 4.99
Market Cap 6434117065
Shares 298,983,135
Volume 1,845,092
Short Ratio
Av. Daily Volume 4,423,008

NewsSee all news

  1. Exelixis Inc (EXEL) Files 10-K for the Fiscal Year Ended on December 31, 2018
  2. Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
  3. New Strong Sell Stocks for February 15th
  4. Implied Volatility Surging for Exelixis (EXEL) Stock Options
  5. Cramer's lightning round: These are the two pot stocks I'm recommending

SEC filingsSee all SEC filings

  1. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 19625834
  2. 8-K - Current report 19622795
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594726
  4. 8-K - Current report 19591064
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19583236

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 2 ongoing.
CABOMETYX (cabozantinib)
Recurrent endometrial cancer
Phase 3 data due 2H 2019.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
Phase 3 trial met primary endpoint - September 24, 2017. Japanese regulatory filing due 1Q 2018.
Esaxerenone (CS-3150)
Essential hypertension
Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018. Approval announced December 19, 2017.
Cabozantinib - CABOSUN
First-Line RCC - cancer
FDA Approval announced January 14, 2019.
Cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Approved April 25 2016.
CABOMETYX (cabozantinib)
Metastatic renal cell cancer (RCC)
Approved November 10, 2015.
Vemurafenib
BRAF V600 Mutation-Positive Advanced Melanoma - Cancer
Phase 3 COMET-2 trial did not meet endpoint December 1 2014
Cabozantinib
Cancer - Castration-Resistant Prostate Cancer
Phase 3 trial initiation announced October 8, 2018.
Cabozantinib
Thyroid Carcinoma
Phase 1 presentation at ASCO 2018.
CABOMETYX (cabozantinib) + Nivolumab and Ipilimumab
Urothelial Carcinoma
Phase 3 data due 2019.
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
Phase 1b trial expansion announced June 1, 2018.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
Phase 3 initiation announced December 5, 2018.
CABOMETYX (cabozantinib) + atezolizumab (TECENTRIQ) - (COSMIC-312)
Hepatocellular Carcinoma
Phase 1 trial initiation announced February 12, 2019.
XL092
Solid tumors

Latest News

  1. Exelixis Inc (EXEL) Files 10-K for the Fiscal Year Ended on December 31, 2018
  2. Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
  3. New Strong Sell Stocks for February 15th
  4. Implied Volatility Surging for Exelixis (EXEL) Stock Options
  5. Cramer's lightning round: These are the two pot stocks I'm recommending
  6. Exelixis Grabs 90% of First Place
  7. Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4
  8. Exelixis Rises as Fourth-Quarter Earnings Beat Estimates
  9. These 'Small Ball' Names Will Outperform the Market in 2019
  10. The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
  11. Edited Transcript of EXEL earnings conference call or presentation 12-Feb-19 10:00pm GMT
  12. Exelixis, Inc (EXEL) Q4 2018 Earnings Conference Call Transcript
  13. Exelixis: 4Q Earnings Snapshot
  14. Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates
  15. Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  16. Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts
  17. Exelixis, Inc. to Host Earnings Call
  18. Q4 Earnings Preview For Exelixis
  19. The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares
  20. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

SEC Filings

  1. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 19625834
  2. 8-K - Current report 19622795
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594726
  4. 8-K - Current report 19591064
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19583236
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19545135
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19500736
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181225057
  9. CT ORDER - Confidential treatment order 181191352
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 181153893